Stem cell treatment and cerebral palsy: Systemic review and meta-analysis

Table 4 Reported serious adverse events

Ref.	Serious adverse events in cell recipient group	Serious adverse events in control group	Allogenic cells	Application route
Chen et al[45], 2013	0/30	0/30		Intrathecal
Huang et al[46], 2018	0/27	0/27	x	Intravenous
Kang et al[47], 2015	0/18	0/18	x (+ immunosuppressant)	Intravenous/intraarterial
Liu et al[40], 2017	0/68	0/34		Intrathecal
Luan et al[44], 2012	1/45	0/49	x	Intraventricular
Min et al[39], 2013	3/36	6/70	x (+ immunosuppressant)	Intravenous
Rah et al[42], 2017	0/57	-		Intravenous
Sun et al[41], 2017	0/63	-		Intravenous
Total	4/344 (1.2%)	6/228 (2.6%)